Stephan Bek
Impact in
- Immunology top 2%
- Psoriasis: Treatment and Pathogenesis
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Hematology top 5%
- Autoimmune and Inflammatory Disorders Research
Papers in
-
- Alcohol Consumption and Health Effects 2
- Co-authors
- Brian G. Feagan (1 shared paper)Jan Wehkamp (1 shared paper)Bruce E. Sands (1 shared paper)Marek Karczewski (1 shared paper)Marc Vandemeulebroecke (1 shared paper)Jacek Karczewski (1 shared paper)Gerard Bruin (1 shared paper)Wolfgang Hueber (1 shared paper)
- Journals
- Analytical and Bioanalytical Chemistry (1 paper)Alimentary Pharmacology & Therapeutics (1 paper)Analytical Chemistry (1 paper)The Pharmacogenomics Journal (1 paper)Gut (1 paper)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Stephan Bek
11 papers receiving 1.8k citations
Stephan Bek's Hit Papers
Peers
Comparison fields: 5 of 93
- Immunology 1.0k
- Hematology 270
- Rheumatology 340
- Genetics 519
- Dermatology 155
Countries citing papers authored by Stephan Bek
This map shows the geographic impact of Stephan Bek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Bek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Bek more than expected).
Fields of papers citing papers by Stephan Bek
This network shows the impact of papers produced by Stephan Bek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Bek. The network helps show where Stephan Bek may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephan Bek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Hit paper breakdown → | 2012 | 1156 |
| 2 | 2009 | 234 | |
| 3 | 2008 | 93 | |
| 4 | 2016 | 83 | |
| 5 | 2017 | 74 | |
| 6 | 2002 | 72 | |
| 7 | 2003 | 61 | |
| 8 | 2005 | 39 | |
| 9 | 2014 | 8 | |
| 10 | 2019 | 4 | |
| 11 | Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B) | 2012 | 2 |
About Stephan Bek
Stephan Bek is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry and Rheumatology, having authored 11 papers that have together received 1.8k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (2 papers), Alcohol Consumption and Health Effects (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers), Natural Antidiabetic Agents Studies (2 papers), Advanced Glycation End Products research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Cytokine Signaling Pathways and Interactions (1 paper) and IL-33, ST2, and ILC Pathways (1 paper). The work is most often cited by research in Immunology (1.0k citations), Hematology (270 citations), Rheumatology (340 citations), Genetics (519 citations) and Dermatology (155 citations). Stephan Bek has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Brian G. Feagan, Jan Wehkamp, Bruce E. Sands, Marek Karczewski, Marc Vandemeulebroecke, Jacek Karczewski, Gerard Bruin, Wolfgang Hueber, Marco Londei and Simon Travis. Their work appears in journals such as Analytical and Bioanalytical Chemistry, Alimentary Pharmacology & Therapeutics, Analytical Chemistry, The Pharmacogenomics Journal and Gut.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.